Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.52 Analyst target: $8.75 Upside: 475.66%
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
See the full interactive analysis & chart →Informational only — not investment advice.